Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.
Income investors heading into July face a friendlier setup than they did just six weeks ago.
Iron Mountain, Tanger, Four Corners, Essential Properties, and Chatham Lodging delivered outsized REIT returns by exploiting price-value gaps during market panics. My disciplined value investing approach focuses on durable business models, strong balance sheets, and buying below intrinsic value, not market timing or headline chasing. IRM and SKT now trade at premium valuations, while EPRT and FCPT remain attractively priced with solid growth and conservative payout ratios; CLDT reached fair value and was exited.
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.
Agree Realty Corporation (NYSE: ADC) (the âCompanyâ) today announced that it will release its second quarter 2026 operating results after the market closes
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes on Thursday, July 30, 2026. A conference call to discuss the Company's operating results is scheduled for Friday, July 31, 2026, at 10:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (833) 461-5787 International (626) 884-3620 .
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.
